Immunotherapy Targeted Therapies Gene Therapy Gene Editing Cell Therapy Music Therapy Combination Treatments Radioactive Treatment Cellular Therapy Drug Development siRNA Therapy Vaccination Regenerative Medicine Universal CAR-T Therapy Combination Therapies RNA Interference CAR T Cell Therapy Non-invasive Techniques Neuroscience Antibody-Drug Conjugates Biocompatibility Alpha-Emitting Therapies Living Medicines Oxygen Treatments Ultrasound Technology Cytokines Viral Therapy Flu Prevention Genetic Engineering CAR T-cell Therapy KRAS Inhibitors Clinical Applications Biotechnology CAR-NK Therapy Electromagnetic Therapy iPSC-derived Therapies Research Institutions CFTR Modulators CAR-T Therapy Drug Delivery Systems Radiation Therapy Long-Acting Biologics T-cell Engagers Longevity Treatments Molecular Biology
Want to see what podcasts are saying about this topic? Search across 140K+ podcasts. Explore Radar
The agreement gives Lilly exclusive development and commercial control outside Korea, with Hanmi taking a $75 million up‑front payment and large milestone and royalty upside.
